Drugs / Lorvotuzumab Mertansine
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00991562 | Dec 2009 → Aug 2013 | plasma cell myeloma | ImmunoGen, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00346255 | Apr 2005 → Mar 2011 | plasma cell myeloma | ImmunoGen, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00346385 | Mar 2002 → Oct 2011 | cutaneous neuroendocrine carcinoma, ovarian cancer, small cell lung carcinoma | ImmunoGen, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT01237678 | Nov 2010 → May 2015 | small cell lung carcinoma | ImmunoGen, Inc. | Terminated | Missed primary |
| Phase 1/2 | NCT00065429 | Apr 2003 → Nov 2008 | small cell lung carcinoma | ImmunoGen, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02452554 | Oct 2015 → Jun 2017 | Wilms tumor, malignant peripheral nerve sheath tumor, neuroblastoma, pleuropulmonary blastoma +2 | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT02420873 | May 2015 → Jun 2017 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 19
| Date | Issuer | Release |
|---|---|---|
| 2013-11-05 | AbbVie | Results ImmunoGen, Inc. Announces Discontinuation of IMGN901 Study in Small-Cell Lung Cancer (SCLC) abbvie.com ↗
announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial's independent Data Monitoring Committee (DMC). |
| 2012-12-10 | AbbVie | Results ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH abbvie.com ↗
The response findings reported for the 39 efficacy-evaluable patients included: Sixty-four percent of patients had a clinical response (minimal response, MR, or better) to treatment and another 31% had stable disease (SD). |
| 2012-09-06 | AbbVie | Results ImmunoGen, Inc. Announces Presentation of New IMGN901 Clinical Data abbvie.com ↗
IMGN901 was able to be administered in combination with a standard etoposide/carboplatin regimen at its full single-agent dose, which speaks to the favorable tolerability profile of this compound. |
| 2011-06-05 | AbbVie | Results ImmunoGen, Inc. Announces Positive Clinical Data Presented on IMGN901 in the Treatment of Multiple Myeloma abbvie.com ↗ |
| 2010-12-04 | AbbVie | Results ImmunoGen, Inc. Announces Presentation of Positive Initial Clinical Data for IMGN901 Used in a Combination Regimen for Multiple Myeloma abbvie.com ↗
ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma. |
| 2010-10-11 | AbbVie | Results ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Data for Lorvotuzumab Mertansine at ESMO Annual Meeting abbvie.com ↗
The data reported today are from an early-stage clinical trial evaluating lorvotuzumab mertansine in CD56+ solid tumors. |
| 2010-08-18 | AbbVie | Regulatory ImmunoGen, Inc.Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer abbvie.com ↗
today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC). |
| 2010-03-08 | AbbVie | Regulatory ImmunoGen, Inc. Announces Orphan Drug Designation Granted to IMGN901 for Treatment of Merkel Cell Carcinoma by US FDA and EU COMP abbvie.com ↗
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). |
| 2009-12-06 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Multiple Myeloma abbvie.com ↗
today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens. |
| 2009-11-17 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma abbvie.com ↗
Meaningful evidence of anticancer activity has been noted among the limited number of patients with MCC who have received IMGN901. |
| 2009-07-31 | AbbVie | Results ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer abbvie.com ↗
In two early-stage clinical trials that enrolled patients whose SCLC had recurred following treatment with standard chemotherapies, IMGN901 administration achieved notable tumor shrinkage and/or sustained stable disease. |
| 2008-12-08 | AbbVie | Results ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting abbvie.com ↗
The findings presented today are from a Phase I, dose-escalation clinical trial that evaluates the TAP compound IMGN901 - used as a single agent - for the treatment of multiple myeloma that has failed the approved therapies for this cancer. |
| 2008-04-08 | AbbVie | Results ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research 2008 Annual Meeting abbvie.com ↗
IMGN901 plus bortezomib (Velcade(R)) demonstrated additive-to-synergistic activity in vivo, as did IMGN901 used in combination with lenalidomide (Revlimid(R)). |
| 2007-12-09 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting for TAP Compound AVE9633 abbvie.com ↗
In the past two days, impressive clinical findings were reported with two TAP compounds - IMGN901 and AVE9633 - in the treatment of multiple myeloma and acute myeloid leukemia, respectively, and highly favorable preclinical data were reported with a third TAP compound, SAR3419, for the treatment of lymphomas. |
| 2007-12-08 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting with Targeted Anticancer Compounds IMGN901 (HuN901-DM1) and AVE1642 abbvie.com ↗
2 patients with multiple myeloma that had failed treatment with a number of prior therapies had an objective response to treatment with IMGN901 (abstract #1174). |
| 2005-11-14 | AbbVie | Results ImmunoGen, Inc. Announces Clinical and Preclinical Findings with TAP Compounds to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics abbvie.com ↗
This poster presentation will feature clinical findings with ImmunoGen's huN901-DM1 product candidate in this ongoing Phase I trial. |
| 2002-11-22 | AbbVie | Results ImmunoGen, Inc. and British Biotech plc Announce Completion of huN901-DM1 Phase I Study abbvie.com ↗
Dr. Tolcher's poster presentation concludes that huN901-DM1 can be safely and feasibly administered for repetitive courses at doses comparable to those that produced antitumor activity in preclinical models. |
| 2002-05-20 | AbbVie | Results ImmunoGen, Inc. and British Biotech plc Announce Presentation of Data from Ongoing Phase I/II Clinical Study of huN901-DM1/BB-10901 at the 2002 Meeting of the American Society of Clinical Oncology abbvie.com ↗ |
| 2000-11-08 | AbbVie | Results ImmunoGen Reports Favorable Preclinical Results for huN901-DM1/BB-10901 abbvie.com ↗
In addition, the TAP showed exceptional anti-tumor activity in mouse studies, even at very low doses. |
All press releases naming this drug 25 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lorvotuzumab Mertansine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452554 ↗ |
| Known as | BB-10901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00065429 ↗ |
| Known as | HUN-901-DM1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743037 ↗ |
| Known as | IMGN901 | “Lorvotuzumab Mertansine (IMGN901)” NCT02420873 ↗ |
| Known as | Lorvotuzumab mertansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743037 ↗ |
| Action | Inhibit | “Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways.” NCT00346255 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways.” NCT00346255 ↗ |
| Route | Intravenous | “I.V. Infusion - See "Arms" for dosage - Once/Week for three weeks - Until Progression of disease.” NCT00065429 ↗ |
| Target | NCAM1 | “Neural cell adhesion molecule 1 binding agent” CHEMBL1743037 ↗ |